Top Story

Potential liver repair drug CF102 issued US patent

September 30, 2014

Can-Fite BioPharma received a US patent for CF102, a drug under development to repair liver cells and function in patients with hepatocellular carcinoma, according to a news release.

CF102, an oral molecular bioavailable drug, acts as an agonist at the A3 adenosine receptor and has demonstrated antitumor effects in multiple phase 1 and 2 clinical trials, resulting in liver cancer cell death, according to Can-Fite.

Meeting News Coverage

Safety, efficacy of sorafenib exposure inconsistent in HCC, RCC patients

September 29, 2014
There was no apparent relationship between exposure to sorafenib and safety and efficacy among patients with hepatocellular carcinoma or renal cell carcinoma, according…
Meeting News Coverage

Patients with advanced pancreatic NET achieved 44-month OS with Afinitor

September 29, 2014
Results from a phase 3 trial presented at the European Society for Medical Oncology 2014 Congress in Madrid showed overall survival of more than 3.5 years in patients…
Meeting News Coverage

Obesity, inflammation during adolescence increased colorectal cancer later in life

September 29, 2014
Adolescent males who were obese or had blood markers that suggested high levels of inflammation demonstrated a higher risk for colorectal cancer later in life, according…
CME CNE
figure

Treatment Decision-Making through the Spectrum of MDS: Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »
CME CNE
figure

Treatment Decision-Making through the Spectrum of MDS: Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »

Filter By:

Potential liver repair drug CF102 issued US patent

September 30, 2014
Can-Fite BioPharma received a US patent for CF102, a drug under development to repair liver cells and function in patients with hepatocellular…
Meeting News Coverage

Safety, efficacy of sorafenib exposure inconsistent in HCC, RCC patients

September 29, 2014
There was no apparent relationship between exposure to sorafenib and safety and efficacy among patients with hepatocellular carcinoma or renal cell…
Meeting News Coverage

Patients with advanced pancreatic NET achieved 44-month OS with Afinitor

September 29, 2014
Results from a phase 3 trial presented at the European Society for Medical Oncology 2014 Congress in Madrid showed overall survival of more than 3.5…
Meeting News Coverage

Obesity, inflammation during adolescence increased colorectal cancer later in life

September 29, 2014
Adolescent males who were obese or had blood markers that suggested high levels of inflammation demonstrated a higher risk for colorectal cancer…
In the Journals

HCC patients in longer waiting time regions for LT showed better overall survival

September 26, 2014
Candidates for liver transplant with hepatocellular carcinoma listed in the long waiting time regions had higher overall survival rates compared with…
figure In the Journals

Provider-based research networks may reduce racial disparities in colorectal cancer therapy

September 26, 2014
African-American patients with stage III colon cancer were more likely to receive early access to innovative treatment at provider-based research…
FDA News

FDA grants orphan drug status to RX-3117 for pancreatic cancer

September 25, 2014
Rexahn Pharmaceuticals recently announced that the FDA has granted orphan drug designation to its cancer-specific nucleoside analog, RX-3117, for the…
figure Cover Story Publication Exclusive

Quest for clinically meaningful PFS benefit an ‘imperfect science’

HemOnc Today, September 25, 2014
Small improvements in study endpoints often serve as the foundation for drug approvals.However, a small but vocal segment of the hematology and…
figure Editorial Publication Exclusive

I’d like to agree with you … but then we’d both be wrong!

HemOnc Today, September 25, 2014
Derek Raghavan, MD, PhD
I sometimes fear that I am a natural curmudgeon, or at the very least a true cynic.If you have read my recent editorials and op-eds, it may seem I…
figure In the Journals

Colorectal cancer task force issues optimal bowel prep guidelines for colonoscopy

September 24, 2014
Inadequate bowel cleansing for colonoscopy causes missed precancerous lesions and higher costs associated with early repeat procedures, according to…
More Headlines »